D&A at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's D&A?
- Cytokinetics (CYTK) reported D&A of $3.38M in Q1 2026.
- How has Cytokinetics's D&A changed year-over-year?
- Cytokinetics's D&A increased by 46.9% year-over-year, from $2.3M to $3.38M.
- What is the long-term trend for Cytokinetics's D&A?
- Over 4 years (2021 to 2025), Cytokinetics's D&A has grown at a 45.2% compound annual growth rate (CAGR), from $2.28M to $10.13M.
- What does D&A mean?
- The non-cash accounting cost of wearing out physical assets or expiring intangible assets.
- How do you interpret D&A?
- Higher values indicate a larger capital base or faster asset write-offs.
- How does D&A compare across companies?
- Standard across all capital-intensive industries.